BioSpace

Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push

Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for treating schizophrenia with its 2024 approval.

By BioSpace

1 min read
Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights